According to filings with the U.S. Securities and Exchange Commission, SMSbiotech, Inc. is raising up to $15,752,800.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About SMSbiotech, Inc.
SMSbiotech is a San Diego based biotech company utilizing a novel human stem cell to advance the field of regenerative medicine. Currently, many conventional drugs and treatments address patients symptoms instead of the root causes of the disease. This approach can result in ongoing health issues like non-healing wounds or diseases we merely live with like COPD. SMSbiotechs patented regenerative technology intends to change this status quo. Its approach addresses the lack of ability of many patients to restore cells and tissues that have been damaged by disease or trauma. The healthy human body has an innate ability to heal and the drive to protect itself. When the mechanisms that signal this response are impaired, the body needs assistance to restore that ability. SMSbiotech has established a newly discovered technology that is largely donor independent and ethically sourced from living, human adults. By using the right source and tapping scientifically into that inherent mechanism for regeneration, therapies and treatments can be developed to assist the human body in healing. SMSbiotech technology will lead to the development of more efficient and relevant medicines that will serve a broad spectrum of patients and reduce the overall costs of healthcare.

To learn more about SMSbiotech, Inc., visit https://www.smsbiotech.com/
SMSbiotech, Inc. Linkedin Page: https://www.linkedin.com/company/smsbiotech/

Contact:
Abdulkader Rahmo, President
760-290-3406
https://www.linkedin.com/in/abdulkader-rahmo-56980827/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.